Analyst On What Biogen's Alzheimer's Drug Means For The Company

Analyst on what Biogen's Alzheimer's drug means for the company

CNBC Television

Why this analyst remains a 'skeptic' on Biogen's new Alzheimer's drug

CNBC Television

What Biogen halted its Alzheimer's drug trial means for biotech investors

CNBC Television

Alzheimer's drug will lead to some societal decisions: Analyst

CNBC Television

Biogen's Alzheimer’s drug could generate ‘$8 billion in peak sales’: Analyst

Biogen Analyst Sees No Clear Growth Driver to Replace Alzheimer's Drug

Bloomberg Television

Biogen Alzheimer's drug may be 'first effort of a clear win': Analyst

Analyst: It's unclear whether Biogen's new Alzheimer's drug will get approved

CNBC Television

Biogen Alzheimer's Drug: Doctors 'won't come out of the gates prescribing' this: Analyst

Evidence to approve Biogen's Alzheimer's drug was not 'sufficient': Penn's Dr. Jason Karlawi

CNBC Television

This analyst breaks down the bull case for Biogen's Alzheimer's drug

CNBC Television

Jim Cramer on FDA resignations connected to the approval of Biogen’s Alzheimer’s drug

CNBC Television

Cantor Fitzgerald's Young on FDA approval for Biogen's Alzheimer drug

CNBC Television

Biogen's Alzheimer's drug trial ripe for downside: Analyst

CNBC Television

Biogen CEO on FDA approval for its Alzheimer's drug

CNBC Television

What’s The Controversy Behind Biogen’s Alzheimer’s Drug?

CNBC

Jefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drug

CNBC Television

FDA Gives Green Light to Biogen's Alzheimer’s Drug

Bloomberg Television

Biogen shares spike after FDA approves Alzheimer's drug

CNBC Television

FDA approves Biogen Alzheimer's treatment

CNBC Television